Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025328 | 0.98 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL5411991 | 0.83 | HDAC3 (0.51) | SMN1; SMN2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL3013357 | 0.79 | KMT2A (0.64) | SMN1; SMN2MEN1KMT2AMAPTNPC1 | |
| SCHEMBL3232775 | 0.79 | HDAC1 (0.49) | SMN1; SMN2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7217485 | 0.78 | CA1 (0.51) | SMN1; SMN2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL3224292 | 0.78 | HDAC1 (0.48) | SMN1; SMN2HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL15224205 | 0.75 | KMT2A (0.68) | SMN1; SMN2MEN1KMT2AMAPTNPC1 | |
| SCHEMBL7494597 | 0.72 | MAPT (0.52) | SMN1; SMN2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL4322685 | 0.72 | MAPK1 (0.58) | SMN1; SMN2KMT2AMAPTNPC1CYP1A2 | |
| SCHEMBL13568860 | 0.72 | HDAC3 (0.47) | SMN1; SMN2HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| EP-1286673-B8 | LIGANDS OF INTEGRIN RECEPTORS | ABBOTT GMBH & CO KG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1286673-B1 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040063934-A1 | Integrin ligands | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-04-01 | — | — | US | disclosed |
| EP-1307443-A2 | NOVEL SUBSTITUTED DIARYL AZEPINE DERIVATIVES AS INTEGRIN LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| EP-1289962-A1 | INTEGRIN LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-12 | — | — | EP | disclosed |
| EP-1286673-A2 | LIGANDS OF INTEGRIN RECEPTORS | Basf Aktiengesellschaft (DE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002014320-A2 | NOVEL SUBSTITUTED DIARYL AZEPINE DERIVATIVES AS INTEGRIN LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001096312-A1 | INTEGRIN LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-20 | — | — | WO | disclosed |
| WO-2001093840-A2 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063934-A1 | Integrin ligands | ITGB3, ITGAV, ITGAL | SMN1; SMN2 3051/4885MEN1 4388/4885KMT2A 4601/4885 |
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | SMN1; SMN2 4254/4885MEN1 4463/4885KMT2A 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.